Back

Hippocampal β-adrenergic system modulates recognition memory reconsolidation

Balbinot, G.; Haubrich, J.

2022-05-18 pharmacology and toxicology
10.1101/2022.05.16.492176 bioRxiv
Show abstract

Targeting reconsolidation with propranolol, a blocker of {beta}-adrenergic receptors ({beta}-ARs), emerged as a potential treatment for maladaptive memories such as those involved in posttraumatic stress disorder (PTSD). Reconsolidation targeting treatments for PTSD are becoming a common practice in the clinic and it is important to unveil any side effects upon non-targeted memories. While previous studies have focused on propranolols effects on the reconsolidation of emotional/distressful memories, the present study asked whether propranolol is involved in the reconsolidation of recognition memories - by assessing its effects on distinct memory components and the role of the hippocampus. Rats performed an object recognition (OR) task where they were exposed to different objects: A and B presented during the sample phase; A and C presented during the reactivation phase; and D in combination of either A, B, or C during a final test. Intra-hippocampal injections of propranolol (5 {micro}g or 10 {micro}g) were conducted immediately after the reactivation session. Propranolol infusions consistently impaired the addition of novel information to the previously consolidated memory trace regardless of dose, and the retention of familiar objects was not affected. Higher doses of propranolol also hindered memory of a familiar object that was not presented during the reactivation session, but was previously placed at the same location where novel information was presented during reactivation. The present results shed light on the role of {beta}-ARs on the reconsolidation of different memory components and argue for the need for further studies examining possible recognition memory deficits following propranolol treatment. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=66 SRC="FIGDIR/small/492176v1_ufig1.gif" ALT="Figure 1"> View larger version (21K): org.highwire.dtl.DTLVardef@69c9f9org.highwire.dtl.DTLVardef@14afbaborg.highwire.dtl.DTLVardef@1d0d0a2org.highwire.dtl.DTLVardef@314e0c_HPS_FORMAT_FIGEXP M_FIG C_FIG Post-traumatic stress disorder is a chronic mental health condition, which may develop following direct or indirect exposure to a traumatic event. The administration of propranolol to individuals affected by this disorder before the reactivation of the trauma-related memory may diminish the symptoms of this mental condition. Here, we show that such treatment may have effects on non-targeted memories, other than the fear/distressful memory. In a series of experiments in rodents, we show that intra-hippocampal infusion of propranolol immediately after recalling and updating a recognition memory trace hampers the reconsolidation of the initial recognition memory trace during recall. This may lead to difficulties in recalling recent events related to declarative memories. In a high dose, propranolol treatment may also affect the conjunctive component (association between multiple elements) of the memory trace - in addition to the effect on the elemental component. This may lead, for example, to difficulties in locating a parked car in a non-usual location after the post-stress traumatic stress disorder therapy with propranolol. HighlightsO_LIWe established the role of the hippocampal {beta}-adrenergic system in the reconsolidation of recognition memories. C_LIO_LIPropranolol treatment may impair the updating of recognition memory traces. C_LIO_LIHigh doses of propranolol may disrupt both elemental and conjunctive components of memory. C_LIO_LIClinical treatment with high doses of propranolol for post-traumatic stress disorder may unintentionally affect non-pathological components of memories. C_LI

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
International Journal of Neuropsychopharmacology
11 papers in training set
Top 0.1%
8.5%
2
British Journal of Pharmacology
34 papers in training set
Top 0.1%
4.9%
3
Journal of Psychiatric Research
28 papers in training set
Top 0.1%
4.9%
4
Scientific Reports
3102 papers in training set
Top 23%
4.9%
5
Neuropsychopharmacology
134 papers in training set
Top 0.6%
4.9%
6
Biological Psychiatry Global Open Science
54 papers in training set
Top 0.1%
4.0%
7
PLOS ONE
4510 papers in training set
Top 39%
3.6%
8
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.1%
3.6%
9
Neuropharmacology
60 papers in training set
Top 0.2%
3.6%
10
Frontiers in Pharmacology
100 papers in training set
Top 1.0%
3.3%
11
ACS Chemical Neuroscience
60 papers in training set
Top 0.7%
2.8%
12
Progress in Neuro-Psychopharmacology and Biological Psychiatry
36 papers in training set
Top 0.3%
2.1%
50% of probability mass above
13
Neuroscience Letters
28 papers in training set
Top 0.2%
2.1%
14
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
62 papers in training set
Top 0.7%
2.1%
15
Journal of Psychopharmacology
14 papers in training set
Top 0.3%
1.7%
16
Frontiers in Psychiatry
83 papers in training set
Top 2%
1.5%
17
International Journal of Molecular Sciences
453 papers in training set
Top 9%
1.5%
18
eLife
5422 papers in training set
Top 47%
1.3%
19
European Journal of Neuroscience
168 papers in training set
Top 0.8%
1.2%
20
Psychopharmacology
59 papers in training set
Top 0.5%
1.2%
21
Alzheimer's Research & Therapy
52 papers in training set
Top 1%
1.2%
22
Biomedicines
66 papers in training set
Top 2%
0.9%
23
Translational Psychiatry
219 papers in training set
Top 4%
0.9%
24
Neurobiology of Learning and Memory
35 papers in training set
Top 0.3%
0.9%
25
Life Sciences
25 papers in training set
Top 1%
0.8%
26
Behavioral Neuroscience
25 papers in training set
Top 0.3%
0.8%
27
Behavioural Brain Research
70 papers in training set
Top 1%
0.8%
28
Journal of Clinical Medicine
91 papers in training set
Top 6%
0.8%
29
Psychological Medicine
74 papers in training set
Top 2%
0.8%
30
Neuroscience
88 papers in training set
Top 3%
0.8%